Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol SCYX
SCYNEXIS
SCYX
94
$2.04arrow_drop_down4.22%-$0.09
High Value
High Quality
Penny Stock

Performance History

Chart placeholder
Key Stats
Open$2.15
Prev. Close$2.13
EPS2.11
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap88215832.00
PE Ratio0.97
LOWHIGH
Day Range1.91
2.15
52 Week Range1.35
3.87
Ratios
P/B Ratio0.75
Revenue-
Operating M. %-692.50%
Earnings$67.04M
Earnings Growth %206.74%
EBITDA Margin %53.10%
ROE %45.86%
EPS2.11

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About SCYNEXIS (SCYX)

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
CEO
Mr. David Gonzalez Angulo M.D.
Headquarters
Jersey City
Employees
36
Exchange
NASDAQ
add SCYNEXIS  to watchlist

Keep an eye on SCYNEXIS

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is SCYNEXIS 's (SCYX) price per share?

The current price per share for SCYNEXIS (SCYX) is $2.04. The stock has seen a price change of -$0.09 recently, indicating a -4.23% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for SCYNEXIS (SCYX)?

For SCYNEXIS (SCYX), the 52-week high is $3.87, which is 89.71% from the current price. The 52-week low is $1.35, the current price is 51.11% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is SCYNEXIS (SCYX) a growth stock?

SCYNEXIS (SCYX) has shown an average price growth of 0.41% over the past three years. It has received a score of 17 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying SCYNEXIS as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is SCYNEXIS (SCYX) stock price performance year to date (YTD)?

As of the latest data, SCYNEXIS (SCYX) has a year-to-date price change of -7.69%. Over the past month, the stock has experienced a price change of -9.73%. Over the last three months, the change has been 40.69%. Over the past six months, the figure is 27.5%. Looking at a longer horizon, the five-year price change stands at -84.43%.

help
Is SCYNEXIS (SCYX) a profitable company?

SCYNEXIS (SCYX) has a net income of $67.04M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 88.27% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -692.5% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $123.71M. Operating income is noted at $72.67M. Furthermore, the EBITDA is $74.21M.

help
What is the market capitalization of SCYNEXIS (SCYX)?

SCYNEXIS (SCYX) has a market capitalization of $88.22M. The average daily trading volume is 169.33K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level